About Pear Bio
Pear Bio is a company based in London (United Kingdom) founded in 2017 by Duleek Ranatunga. Pear Bio has raised $14.15 million across 3 funding rounds from investors including Merck, Octopus Ventures and Hoxton Ventures. The company has 33 employees. Pear Bio offers products and services including Personalized Testing Services and Drug Discovery Services. Pear Bio operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Xilis, among others.
- Headquarter London, United Kingdom
- Employees 33
- Founders Duleek Ranatunga
- SectorsHealthcare
- Website pearbio.com
- Social LinkedIn X
- Legal Name Ourotech Limited
- Date of Incorporation 29 Oct, 2019
- Jurisdiction LONDON, ENGLAND
- Total Equity Funding$14.15M (USD)
in 3 rounds
- Latest Funding Round$14.15M (USD), Series A
Apr 2023
- InvestorsMerck
& 7 more
- Employee Count33
Products & Services of Pear Bio
Pear Bio offers a comprehensive portfolio of products and services, including Personalized Testing Services and Drug Discovery Services.
Tests cancer treatments using 3D immune-microtumors to predict patient responses.
Identifies new targets and develops therapies for high unmet need cancers.
Funding Insights of Pear Bio
Pear Bio has successfully raised a total of $14.15M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14.15 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.15M
- Total Rounds 3
- Last Round Series A — $14.15M
- Investors Count 8
All 3 funding rounds of Pear Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $14.15M | Series A | – | Octopus Ventures | |
| Jan 2019 | – | Seed | – | – | |
| Jun 2017 | – | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Pear Bio
Pear Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Octopus Ventures and Hoxton Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and support for founders in technology and health sectors. | – | octopusventures.com | - | |
VC and PE firm focused on seed and early stage tech companies | – | hoxtonventures.com | London, United Kingdom | |
- | – | cristagalli.com | - | |
Venture capital and accelerator services are provided across multiple sectors. | – | sosv.com | Cork, Ireland | |
Venture capital investments are made in European tech startups from day-zero to seed. | – | fly.vc | - | |
Compound is recognized as a thesis-driven investment firm. | – | compound.vc | New York, United States | |
Sector-agnostic acceleration is provided to startups through global programs. | – | k-startupgc.org | Seongnam-si, South Korea | |
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany |
Investor details for Pear Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pear Bio
7 people are tracked at Pear Bio (4 in leadership, 3 in team); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
Duleek Ranatunga | Founder & CEO | Leadership |
Eleonora Peerani | Director Of Precision Medicine R&d | Leadership |
Matt Williams | Chief Medical Officer (precision Medicine) | Leadership |
John Curran | COO & Laboratory Director | Leadership |
Samuel Ordu | Full Stack Cloud Developer | Team |
Jay Kearney | Principal Immuno-oncology Scientist | Team |
Thomas Richardson | Senior Biomaterials Engineer | Team |
Complete people profiles for Pear Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pear Bio
3 dated milestones of Pear Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Pear Bio is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $14.2M.
Competitors of Pear Bio
Pear Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Xilis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | – | Developer of AI-based platform for lab-grown human tissues | |
| xilis.com | 2019 | Durham, United States | $116.26M | 55 | Micro-organ sphere technologies for oncology drug discovery are developed. | |
| carcinotech.co.uk | 2018 | Edinburgh, United Kingdom | $7.35M | 1 | Provides 3D tumor models and assays for cancer research and preclinical testing services. | |
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| parallel.bio | 2020 | Cambridge, United States | $25.43M | 6 | Limited information available |
Detailed competitors of Pear Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pear Bio
The website of Pear Bio (pearbio.com) receives about 1K visits a month.
- Monthly visits1K
▲ 92.3% vs previous month
Latest news on Pear Bio
Complete news archive for Pear Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pear Bio
10 companies that operate in the same segment as Pear Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pear Bio
Pear Bio was founded in 2017.
Pear Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Duleek Ranatunga is the current CEO of Pear Bio. They have also founded this company.
Pear Bio is a funded company, having raised a total of $14.15M across 3 funding rounds to date.
Pear Bio has 33 employees.
Pear Bio develops microfluidic chip for cancer drug research. The device combines tissue engineering, microfluidics, and biomaterials to represent how drugs are infused, distributed and exposed to the tumor over multiple passes during a chemo regimen. It also maps the spread of cancer using 3D imaging.
Pear Bio's top competitors include Newcells Biotech, InSphero and Vivodyne.
Pear Bio offers Personalized Testing Services and Drug Discovery Services.
Pear Bio has 8 investors. Key investors include Merck, Octopus Ventures, Hoxton Ventures, Crista Galli Ventures, and SOSV.
Pear Bio operates through Ourotech Limited.